Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > To Peladawn
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(539)
•••
Comment by Peladawnon Jun 23, 2024 9:56am
66 Views
Post# 36102139

RE:RE:RE:RE:RE:RE:RE:RE:RE:To Peladawn

RE:RE:RE:RE:RE:RE:RE:RE:RE:To PeladawnItntdf.....re: your reference to the absolute mess going on in the Middle East (not just Gaza fyi)

The Trump administration brought a historic level of peace to the Middle East (try actually reading about some day) with the signing of the Abraham Accord, which The Mullahs of Iran absolutely despised, and then along came the stumbling bumbler in chief, who, in his brilliant quest to reverse anything Trump, reversed the Trump sanctions against Iran, (which had Iran close to broke) allowing Iran access to many billions in oil revenue annually, with which of course they stoked up the war coffers of Hamas, Hezbollah, The Houthi's, and all their other proxies. The mess we now see in Gaza has absolutely nothing to do with Trump, and absolutely everything to do with Biden, in spite of your allegations to the contrary. Oh, and Btw, Iran is now tripling the size of their nuclear enrichment program and thanks to ol' Joe, are on the very verge of having a nuclear weapon.

https://apnews.com/article/joe-biden-donald-trump-iran-united-states-united-nations-aa8f38fa3bf7de3c09a469ec91664a3c
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities